Point72 Asset Management L.P. Buys 299,798 Shares of Annexon, Inc. (NASDAQ:ANNX)

Point72 Asset Management L.P. lifted its position in shares of Annexon, Inc. (NASDAQ:ANNX - Free Report) by 5.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,626,796 shares of the company's stock after purchasing an additional 299,798 shares during the period. Point72 Asset Management L.P. owned 5.28% of Annexon worth $28,865,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. E Fund Management Co. Ltd. boosted its holdings in shares of Annexon by 36.0% during the fourth quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company's stock worth $79,000 after purchasing an additional 4,086 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Annexon by 6.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 63,402 shares of the company's stock worth $325,000 after buying an additional 4,092 shares during the period. Comerica Bank lifted its holdings in Annexon by 22.7% in the fourth quarter. Comerica Bank now owns 23,183 shares of the company's stock worth $119,000 after buying an additional 4,283 shares during the period. Wellington Management Group LLP lifted its holdings in Annexon by 1.8% in the fourth quarter. Wellington Management Group LLP now owns 268,166 shares of the company's stock worth $1,376,000 after buying an additional 4,806 shares during the period. Finally, Rhumbline Advisers lifted its holdings in Annexon by 4.3% in the fourth quarter. Rhumbline Advisers now owns 141,852 shares of the company's stock worth $728,000 after buying an additional 5,854 shares during the period.

Analyst Ratings Changes

Several brokerages have commented on ANNX. Needham & Company LLC lowered their price objective on shares of Annexon from $16.00 to $11.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. HC Wainwright lowered their price objective on shares of Annexon from $20.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th.

Annexon Stock Up 0.5%

Shares of ANNX stock traded up $0.01 during trading hours on Tuesday, hitting $2.10. 1,454,145 shares of the company's stock traded hands, compared to its average volume of 1,784,033. The stock has a market cap of $230.40 million, a price-to-earnings ratio of -2.00 and a beta of 1.24. The stock's fifty day simple moving average is $1.89 and its two-hundred day simple moving average is $3.58. Annexon, Inc. has a 12-month low of $1.29 and a 12-month high of $7.85.

Annexon (NASDAQ:ANNX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.07). On average, equities analysts forecast that Annexon, Inc. will post -0.96 earnings per share for the current fiscal year.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.